MAPT and Alzheimer disease: These concentrations are both close to the estimated steady state trough brain concentration of MT and its pharmacologically active metabolites (0.18 μm) at the minimum effective dose for treatment of AD and the minimum brain concentration (0.13 μm) required for beneficial effects on behavior and pathology in Tau transgenic mice.